GLP1R and type 2 diabetes mellitus: Several cardiovascular clinical studies (CVOTs) on GLP-1 receptor agonists have shown that these agents, as well as being safe, are able to significantly reduce the risk of individual major adverse cardiovascular events (MACE), all-cause mortality, hospitalization for heart failure, as well as to slow worsening of renal function in patients with T2D.